New hope for kids with focal seizures: cenobamate trial underway

NCT ID NCT05067634

Ongoing Disease control Sponsor: SK Life Science, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This phase 3 trial is testing the safety and tolerability of the drug cenobamate (Xcopri) in 140 children aged 2 to 17 with partial-onset (focal) seizures. Researchers will monitor side effects, lab results, and drug levels in the blood. The study is open-label, meaning everyone knows they are receiving the drug, and it is currently active but not recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cenobamate (Xcopri)
What this could lead to: If successful, this could provide a new treatment option to help control focal seizures in children, potentially reducing seizure frequency.
What could go wrong: This is an open-label study without a placebo group, so results may be less definitive. Side effects are possible, and the drug may not work for all children.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

focal epilepsy visual epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARTIAL EPILEPSY

Contacts and locations

Locations

Ajou University Hospital

Suwon, South Korea
Bethesda Gyermekkorhaz

Budapest, Hungary
Boston Children's Health Physicians - Neurology at Hawthorne

Hawthorne, New York, 10532, United States
Centrum Medyczne Plejady

Krakow, Poland
Charite University Hospital

Berlin, Germany
Child Neurology Consultants of Austin

Austin, Texas, 78731, United States
Children's Health Queensland Hospital and Health Service

South Brisbane, Australia
Chungbuk National University Hospital

Cheonju, South Korea
Cincinnati Children's Hospital

Cincinnati, Ohio, 45229, United States
Cleveland Clinic Main Campus

Cleveland, Ohio, 44195, United States
Clinical Integrative Research Center of Atlanta

Sandy Springs, Georgia, 30328, United States
Connecticut Children's Medical Center

Hartford, Connecticut, 06106, United States
Duke University Hospital

Durham, North Carolina, 27710, United States
Hospital Infantil Universitario Niño Jesús

Madrid, Spain
Hospital Sant Joan de Déu Barcelona

Barcelona, Spain
Hospital Universitari Vall d'Hebrón

Barcelona, Spain
Hospital Universitario Virgen del Rocío

Seville, Spain
Korea University Guro Hospital

Seoul, South Korea
Le Bonheur Children's Hospital

Memphis, Tennessee, 38103, United States
Lucile Packard Children's Hospital Stanford

Palo Alto, California, 94304, United States
Mayo Clinic - Rochester

Rochester, Minnesota, 55905, United States
Mid-Atlantic Epilepsy and Sleep Center

Bethesda, Maryland, 20817, United States
Niepubliczny Zaklad Opieki Zdrowotnej - Centrum Neurologii Dzieciecej i Leczenia Padaczki

Kielce, Poland
Northeast Regional Epilepsy Group

Hackensack, New Jersey, 07601, United States
Northeast Regional Epilepsy Group - Morristown

Morristown, New Jersey, 07960, United States
Országos Klinikai Idegtudományi Intézet, Neurológiai Osztály

Budapest, Hungary
Phoenix Children's Hospital

Phoenix, Arizona, 85016, United States
Royal Children's Hospital Melbourne

Parkville, Australia
SMG-SNU Boramae Medical Center

Seoul, South Korea
Semmelweis University Dept. Of Paediatrics

Budapest, Hungary
Seoul National University Hospital

Seoul, South Korea
Servus Salvus Egészségügyi Szolgáltató Kft.

Budapest, Hungary
Severance Hospital

Seoul, South Korea
Sydney Children's Hospital - Randwick

Randwick, Australia
Wojewódzki Specjalistyczny Szpital Dziecięcy im. św. Ludwika w Krakowie

Krakow, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.